Stem cell transplantation as rescue therapy for refractory crohn’s disease: A sytematic review

##plugins.themes.academic_pro.article.sidebar##

Published Feb 24, 2015
Download
pdf
Vol. 92 No. 11 (2014): Issue Nov 2014

##plugins.themes.academic_pro.article.main##

Labidi Asma
Serghini Meriem
Ben Mustapha Nadia
Fekih Monia
Boubaker Jalel
Filali Azza

Abstract

Background: Crohn's disease is a chronic relapsing- remitting affection. It has a strong immunologic component which represent the target of standard therapies including immunosppressants and biological therapies. However, many patients remain refracory or intolerant to these therapies.

Aim: The aim of this review is to determine the effects of stem cell transplantation in patients with refractory Crohn's disease.

Methods: Systematic review of observational studies, clinical trials and case reports that focused on the effectiveness and safety of stem cell transplantation in patients with refractory Crohn's disease. Results: Hematopoietic stem cell transplantation seems to be efficient in maintaining clinical and endoscopic remission in patients with Crohn's disease refractory or intolerant to current therapies. However, it has been associated to high morbidity and mortality due to chemotherapy. Mesenchymal stem cell transplantation could induce remission in patients with fistulising refractory Crohns disease with no severe side effects. Its impact on luminal Crohns disease is still controversial.

Conclusion: Stem cell transplantation seems to hold promising in patients with refractory Crohn's disease. However, because of the high morbidity and mortality related to chemotherapy, hematopoietic stem cell transplantation should be used as last resort to control this disease. Effectiveness of mesenchymal stem cell transplantation in luminal Crohn's disease has yet to be proven.

Keywords:

maladie de Crohn réfractaire; cellules souches hématopoiétiques; cellules souches mésenchymateuse

##plugins.themes.academic_pro.article.details##

References

  1. Prockop DJ. Marrow stromal cells as stem cells for non hematopoietic tissues. Science 1997;276:71-4.
  2. Marmont AM. Stem cell transplantation for autoimmune disordesrs. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol 2004;17:223-32
  3. In 't Anker PS, Noort WA, Scherjon SA, et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 2003;88:845-52
  4. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogenic and autologous transplantation for haematological diseases, solid tumors and immune disorders: Definitions and current practice in Europe. Bone Marrow transplantat 2006 ; 37:439-49.
  5. Musso M, Porretto F, Crescimanno A, Bondi F, Polizzi V, ScaloneR. Crohn's disease complicated by relapsed extranodal Hodgkin's lymphoma: prolonged complete remission after unmanipulated PBPC autotransplant. Bone Marrow Transplant 2000;26:921-3
  6. Kashyap A, Forman SJ. Autologous bone marrow transplantationfor nonHodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease.Br J Haematol 1998;103:651-2
  7. Soderholm JD, Malm C, Juliusson G, Sjodahl R. Long-term endoscopic remission of Crohn disease after autologous stem cell transplantation for acute myeloid leukaemia. Scand JGastroenterol 2002;37:613-6
  8. Hawkey CJ. Stem cell transplantation for Crohn's disease. Best Pract Res Cl Haematol 2004;17: 317-3255
  9. Hasselblatt P, Drognitz K, Potthoff K et al. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther. 2012;36:725-35 drugs. Clin Exp Immunol 2002; 128: 255-66.
  10. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128: 255-66. Crohn's disease. Dig Liver Dis 2011; 43: 946-52.
  11. Clerici M, Cassinotti A, Onida F, et al. Immunomodulatory effects of unselected haematopoietic stem cells autotransplantation in refractory Crohn's disease. Dig Liver Dis 2011; 43: 946-52. Crohn's disease. J Crohns Colitis 2011;5: 543-9.
  12. Hommes DW, Duijvestein M, Zelinkova Z, et al. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease. J Crohns Colitis 2011;5: 543-9.
  13. . Burt RK, Traynor A, Oyama Y, Craig R. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn's disease. Blood 2003;101:2064-6
  14. Cassinotti A, Annaloro C, Ardizzone S,et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.Gut. 2008 ;57:211-7 refractory Crohn disease: long-term follow-up Blood 2010;116:6123-32.
  15. Burt RK, Craig RM, Milanetti F, et al. Autologous non myeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up Blood 2010;116:6123-32.
  16. van Laar JM, Farge D, Sont JK, et al. The ASTIS trial: autologous stem cell transplantation versus iv pulse cyclophsophamide in poor prognosis systemic sclerosis, first results. Ann Rheum Dis 2012; 71: 151.
  17. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113:214-23.
  18. Duijvestein M, van den Brink GR, Hommes DW. Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. J Crohns Colitis 2008;2:99-106.
  19. Miura Y, Thoburn CJ, Bright EC, et al. Characterization of the T-cell repertoire in autologous graft versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD. Blood 2001;98:868-76
  20. Kawada H, Fujita J, Kinjo K, et al. Non hematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004;104:3581-7
  21. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284: 143-7.
  22. Zappia E, Casazza S, Pedemonte E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005;106:1755-61.
  23. Chavakis E, Urbich C, Dimmeler S. Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol 2008;45:514-22
  24. Tolar, K. Le Blanc, A. Keating, and B. R. Blazar, “Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 2010; 28:1446-55
  25. Horwitz EM, Prockop DJ, Fitzpatrick LA , et al. Transplant ability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfect. Nat Med 1999;5:309-13
  26. Kawada H, Fujita J, Kinjo K et al., “Non hematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004;104: 3581-7.
  27. Crisostomo PR, Markel TA, Wang Y, Meldrum DR. Surgically relevant aspects of stem cell paracrine effects. Surgery 2008; 143:577.
  28. Spaggiari GM, Capobianco A, Abdelrazik H, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111:1327
  29. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113:6576.
  30. Gerdoni E, Gallo B, Casazza S, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007; 61:219.
  31. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010;59:1662-9
  32. Yong Lee W, Joo Park K, Beom Cho Y et al. Autologous Adipose Tissuederived Stem Cells Treatment Demonstrated Favorable and Sustainable Therapeutic Effect for Crohn's Fistula. Stem Cells. 2013 doi: 10.1002/stem.1357
  33. Ciccocioppo R, Bernardo ME, Sgarella A et al. Autologous bone marrowderived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011 ;60:788-98.
  34. Lalu MM, McIntyre L, Pugliese C, et al. Safety of Cell Therapy with Mesenchymal Stromal Cells (safe cells): A Systematic Review and MetaAnalysis of Clinical Trials. PLoS ONE 2012;7: e47559
  35. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 2009;108: 759-69